Efficacy and safety of two dosages of canrenone as add-on therapy in hypertensive patients taking ace-inhibitors or angiotensin II receptor blockers and hydrochlorothiazide at maximum dosage in a randomized clinical trial: The ESCAPE-IT trial

G. Derosa, P. Maffioli, M. D'Avino, C. Sala, A. Mugellini, V. Vulpis, S. Felis, L. Guasti, R. Sarzani, A. Bestetti, M. Vanasia, G. Gaudio, the ESCAPE-IT Trial Investigators group

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)47-54
Number of pages8
JournalCardiovascular Therapeutics
Volume35
Issue number1
DOIs
Publication statusPublished - 2017

Keywords

  • Angiotensin II receptor blockers
  • Angiotensin-converting enzyme inhibitors
  • Canrenone
  • Hydrochlorothiazide
  • Hypertension
  • aldosterone
  • angiotensin receptor antagonist
  • brain natriuretic peptide
  • canrenone
  • creatinine
  • dipeptidyl carboxypeptidase inhibitor
  • galectin 3
  • hydrochlorothiazide
  • potassium
  • triacylglycerol
  • urea
  • uric acid
  • angiotensin 1 receptor antagonist
  • antihypertensive agent
  • biological marker
  • mineralocorticoid antagonist
  • thiazide diuretic agent
  • add on therapy
  • Article
  • blood pressure
  • controlled study
  • drug dose comparison
  • drug efficacy
  • drug safety
  • drug tolerability
  • drug withdrawal
  • essential hypertension
  • estimated glomerular filtration rate
  • female
  • glucose blood level
  • heart rate
  • human
  • insulin resistance
  • major clinical study
  • male
  • multicenter study
  • open study
  • parallel design
  • phase 4 clinical trial
  • priority journal
  • pulse pressure
  • randomized controlled trial
  • side effect
  • urea blood level
  • aged
  • blood
  • clinical trial
  • combination drug therapy
  • comparative study
  • drug effects
  • hypertension
  • Italy
  • middle aged
  • pathophysiology
  • time factor
  • treatment outcome
  • Aged
  • Angiotensin II Type 1 Receptor Blockers
  • Angiotensin-Converting Enzyme Inhibitors
  • Antihypertensive Agents
  • Biomarkers
  • Blood Pressure
  • Drug Therapy, Combination
  • Female
  • Humans
  • Male
  • Middle Aged
  • Mineralocorticoid Receptor Antagonists
  • Sodium Chloride Symporter Inhibitors
  • Time Factors
  • Treatment Outcome

Cite this